Xiaogang Zhang1, Shu Xu, Qinxiang Tan, Longgen Liu. 1. Institute for the Study of Liver Diseases, The Third Hospital of Changzhou, Changzhou 213000, China. Electronic address: gangxiaozhang1@126.com.
Abstract
AIM: Heparanase-2 expression has been suggested to up-regulate in several types of human cancers. However, the expression patterns of heparanase-2 in gastric cancer and its effect on prognosis of gastric cancer patients are unclear. METHODS: In this study, the methods of tissue microarray, immunohistochemistry (IHC), and western blot were used to investigate heparanase-2 expression in gastric cancer and the adjacent non-cancerous tissues. Heparanase-2 expression was analyzed by immunohistochemistry in 95 clinicopathologically characterized gastric cancer cases. In addition Fisher's exact test, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the results. RESULTS: High expression of cytoplasmic heparanase-2 was observed in 70.5% (67/95) of gastric cancer, when compared with its normal counterpart. Overexpression of heparanase-2 was correlated with tumor size and differentiation (P<0.05). Further analysis showed that a significant correlation between high expression of heparanase-2 and favorable prognosis (P<0.05). In multivariate analysis, high expression of heparanase-2 was evaluated as an independent prognostic factor in gastric cancer (P<0.05). CONCLUSIONS: Our data suggest for the first time that the high expression of heparanase-2 is associated significantly with tumor growth and differentiation. Importantly, heparanase-2 may be a potential molecular marker for predicting prognosis of gastric cancer.
AIM: Heparanase-2 expression has been suggested to up-regulate in several types of humancancers. However, the expression patterns of heparanase-2 in gastric cancer and its effect on prognosis of gastric cancerpatients are unclear. METHODS: In this study, the methods of tissue microarray, immunohistochemistry (IHC), and western blot were used to investigate heparanase-2 expression in gastric cancer and the adjacent non-cancerous tissues. Heparanase-2 expression was analyzed by immunohistochemistry in 95 clinicopathologically characterized gastric cancer cases. In addition Fisher's exact test, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the results. RESULTS: High expression of cytoplasmic heparanase-2 was observed in 70.5% (67/95) of gastric cancer, when compared with its normal counterpart. Overexpression of heparanase-2 was correlated with tumor size and differentiation (P<0.05). Further analysis showed that a significant correlation between high expression of heparanase-2 and favorable prognosis (P<0.05). In multivariate analysis, high expression of heparanase-2 was evaluated as an independent prognostic factor in gastric cancer (P<0.05). CONCLUSIONS: Our data suggest for the first time that the high expression of heparanase-2 is associated significantly with tumor growth and differentiation. Importantly, heparanase-2 may be a potential molecular marker for predicting prognosis of gastric cancer.
Authors: Miriam Gross-Cohen; Sari Feld; Ilana Doweck; Gera Neufeld; Peleg Hasson; Gil Arvatz; Uri Barash; Inna Naroditsky; Neta Ilan; Israel Vlodavsky Journal: Cancer Res Date: 2016-03-24 Impact factor: 12.701
Authors: Helen M Browning; Frances M D Gulland; John A Hammond; Kathleen M Colegrove; Ailsa J Hall Journal: Philos Trans R Soc Lond B Biol Sci Date: 2015-07-19 Impact factor: 6.237
Authors: Helen M Browning; Karina Acevedo-Whitehouse; Frances M D Gulland; Ailsa J Hall; Jeanie Finlayson; Mark P Dagleish; Karen J Billington; Kathleen Colegrove; John A Hammond Journal: Proc Biol Sci Date: 2014-12-07 Impact factor: 5.349